Microsphere and protein coupling method
By using a cleaning solution of sodium dodecylbenzenesulfonate and sodium cholate for ultrasonic cleaning and activation, the problems of agglomeration and wall staining during the coupling of nano microspheres and proteins were solved, and the dispersion of the conjugate was improved and Stability reduces preparation costs and achieves more efficient antibody or antigen labeling effects.
Patent Information
- Application Number
- CN202411316529.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, there are agglomeration and wall-touching phenomena during the coupling process between nano microspheres and proteins, resulting in poor dispersion and high economic costs. In particular, the specific biomolecules used in the biological affinity method are relatively expensive to prepare and physical adsorption. The effect is weak and is easily affected by the external environment.
Ultrasonic cleaning and activation are carried out using a cleaning solution including sodium dodecylbenzenesulfonate and sodium cholate to improve the dispersion of microspheres and ensure the stability of microspheres and proteins through multiple steps such as activation, coupling and blocking. Coupling reduces agglomeration and wall-touching.
The number of microsphere-labeled antibodies or antigens is increased, the cost of use of antibodies or antigens is reduced, the dispersion and stability of the conjugates is enhanced, the detection sensitivity is improved, and the preparation cost is saved.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of immunodiagnosis, and in particular to a method for coupling microspheres with proteins. Background Art
[0002] Nanospheres are generally polymerized from polymers, such as polystyrene, chitosan, polyacrylic acid, silica and other materials polymerized into nano-scale microspheres. Nanospheres are widely used in in vitro diagnostic reagents. Nanospheres are usually coupled to proteins through chemical bonding, physical adsorption and bioaffinity. Among them, the chemical bonding method is mainly to modify some reactive groups on the surface of nanospheres, such as carboxyl, hydroxyl, aldehyde, etc., and then activate the reactive groups through activators such as EDC, NHS, glutaraldehyde, NaBH3CN and other activators, and then chemically bond with the amino groups on the antibody / antigen, that is, the microspheres are coupled with the antibody / antigen, and then the excess binding sites that are not coupled are blocked with chemicals with specific groups. The physical adsorption method is to achieve the coupling of the two through non-specific interactions between nanospheres and proteins, such as electrostatic adsorption, hydrophobic interaction, etc. The bioaffinity method uses the specific recognition between biological molecules, such as antigen and antibody reactions, biotin and avidin systems, etc., to achieve the coupling of nanospheres and proteins.
[0003] When chemical methods are used for coupling, in order to achieve the detection requirements after the immune response, fluorescent dye molecules, photosensitizers and other chemical substances will be adsorbed or embedded in the nanoparticles through methods such as embedding, self-assembly, chemical bonding, copolymerization, etc. These organic substances are usually highly hydrophobic. Even if the surface of the nanoparticles is modified with hydrophilic groups, they may aggregate and settle during the antibody coupling process. Since the physical adsorption force is relatively weak, under the influence of the external environment, such as changes in temperature and ionic strength, it is easy to cause the aggregation of nanoparticles and proteins. The specific biological molecules used in the bioaffinity method, such as antibodies, avidins, etc., usually have a high preparation cost, which increases the economic cost of the entire coupling process and is not suitable for production applications. Summary of the invention
[0004] In view of this, the technical problem to be solved by the present invention is to provide a method for coupling microspheres with proteins. The method for coupling microspheres with proteins provided by the present invention can improve the dispersibility of the microspheres during the labeling process, thereby increasing the effect of the number of antibodies / antigens labeled with the microspheres.
[0005] The present invention provides a method for coupling microspheres with proteins, comprising the following steps:
[0006] Step 1, mixing the microspheres with a cleaning solution and then performing ultrasonic cleaning;
[0007] Step 2, activating the microspheres cleaned in step 1;
[0008] Step 3, taking the activated microspheres and mixing them with the cleaning solution, and then ultrasonically cleaning them again;
[0009] Step 4, mixing the microspheres washed in step 3 with the protein for coupling reaction;
[0010] Step 5, taking the microspheres after coupling in step 4, blocking them, and obtaining a conjugate of microspheres and protein;
[0011] The cleaning solution comprises sodium dodecylbenzene sulfonate and sodium cholate.
[0012] Compared with the prior art, the steps of the method for coupling microspheres to proteins provided by the present invention affect each other, and the component solutions cooperate with each other, thereby improving the agglomeration and wall adhesion of the microspheres during the labeling process, thereby achieving the purpose of increasing the number of antibodies or antigens labeled with the microspheres, thereby saving the cost of antibodies or antigens and achieving better technical effects.
[0013] In some embodiments, each 100 mL of the cleaning solution contains 0.0001-0.01 g of sodium dodecylbenzene sulfonate and 0.0001-0.01 g of sodium cholate.
[0014] Compared with the cleaning solution in the prior art, the cleaning solution provided by the present invention can better improve the agglomeration and wall adhesion of the microspheres during the marking process, thereby obtaining a more accurate technical effect. In the cleaning solution within the above concentration range, the components cooperate better with each other and have stronger compatibility, which can better improve the agglomeration and wall adhesion of the microspheres during the marking process, thereby obtaining a more accurate technical effect.
[0015] In some specific embodiments, each 100 mL of the cleaning solution contains 0.01 g of sodium dodecylbenzene sulfonate and 0.0001 g of sodium cholate.
[0016] In some specific embodiments, each 100 mL of the cleaning solution contains 0.0001 g of sodium dodecylbenzene sulfonate and 0.01 g of sodium cholate.
[0017] In some specific embodiments, each 100 mL of the cleaning solution contains 0.005 g of sodium dodecylbenzene sulfonate and 0.005 g of sodium cholate.
[0018] Experiments show that at the above concentrations, the cleaning liquid components cooperate best with each other and have the strongest compatibility, thereby obtaining the most accurate technical effect.
[0019] In some embodiments, the microspheres include at least one of fluorescent microspheres, donor microspheres, and acceptor microspheres.
[0020] Preferably, the raw material of the microspheres includes at least one of polystyrene, chitosan, polyacrylic acid and silicon dioxide.
[0021] Preferably, the surface marker of the microspheres comprises at least one of fluorescence, radioisotope, enzyme, biotin, antibody and chemiluminescent group.
[0022] More preferably, the microspheres are acceptor microspheres.
[0023] In some embodiments, after the ultrasonic cleaning, the microspheres are centrifuged and the supernatant is discarded;
[0024] Preferably, the centrifugal speed is 10000-20000 rpm, and the centrifugal time is 10-15 min;
[0025] More preferably, the centrifugal speed is 18000 rpm and the centrifugal time is 15 min.
[0026] In some embodiments, in step 2, the activation comprises mixing the microspheres, the diluent and the activating agent, and incubating them by shaking.
[0027] In some embodiments, the activating agent comprises at least one of EDC, NHS, glutaraldehyde and NaBH3CN, and the diluent comprises at least one of MES buffer, Hepes buffer and PBS buffer.
[0028] Preferably, the activation reaction temperature is 25-40° C., and the shaking incubation is performed at 500-1000 rpm for 15-30 min.
[0029] The activation reaction temperature was 30° C., and the shaking incubation was performed at 800 rpm for 30 min.
[0030] In some embodiments, in step 4, the coupling reaction comprises taking a coupling buffer to suspend the washed microspheres, mixing with the protein, and incubating by shaking, wherein the coupling buffer comprises at least one of a Hepes buffer, a PBS buffer, and a boric acid buffer, and the protein comprises an antibody or an antigen;
[0031] Preferably, in the incubation solution, the concentration of the microspheres is 30-70% (w / v), the concentration of the protein is 1%-30% (w / v), the incubation temperature is 25-40° C., and the shaking incubation is performed at 500-1000 rpm for 2-4 hours;
[0032] More preferably, in the incubation solution, the concentration of the microspheres is 50% (w / v), the concentration of the protein is 30% (w / v), the incubation temperature is 30° C., and the shaking incubation is performed at 800 rpm for 4 hours.
[0033] In some embodiments, in step 5, the blocking comprises taking the microspheres and incubating them with a blocking solution, wherein the blocking solution comprises at least one of BSA, glycine, ethanolamine, casein and carboxymethoxyamine;
[0034] Preferably, the reaction temperature of the blocking is 25-40°C, and the blocking is performed by shaking and incubating at 500-1000 rpm for 15-30 min;
[0035] More preferably, the blocking reaction temperature is 30° C., and the blocking is performed by shaking and incubating at 800 rpm for 30 min.
[0036] In some embodiments, the blocked solution is centrifuged, the supernatant is discarded, and then ultrasonically cleaned and centrifuged again with water, and the resulting precipitate is mixed with a buffer for storage, and the buffer includes at least one of a Tris buffer, a Hepes buffer, and a PBS buffer;
[0037] Preferably, the storage temperature is 2-8°C
[0038] More preferably, the storage temperature is 4°C.
[0039] Experiments show that compared with the conjugates of microspheres and proteins in the prior art, the conjugate prepared by the above method has the best mutual influence effect between its steps and the closest cooperation between the component solutions, which can better improve the agglomeration and wall adhesion of the microspheres during the labeling process, achieve the purpose of a better number of antibodies or antigens labeled with microspheres, thereby saving the cost of antibodies or antigens and obtaining more accurate technical effects.
[0040] The invention provides a conjugate prepared by the method.
[0041] The invention provides application of the conjugate in preparing a detection kit.
[0042] The invention provides a detection kit, comprising the conjugate.
[0043] The invention provides a detection method, comprising using the detection kit to detect a sample.
[0044] The present invention provides a method for coupling microspheres with proteins, which can improve the dispersibility of microspheres during the labeling process, improve the agglomeration and wall-sticking phenomena of microspheres during the labeling process, and make the microspheres in a state of good dispersibility during activation and coupling, thereby improving the activation efficiency and coupling efficiency, achieving the effect of increasing the number of antibodies / antigens labeled with microspheres, thereby saving the cost of antibodies / antigens. When the method of the present invention is applied to the preparation of a detection kit, it can effectively improve the detection sensitivity of the reagent. DETAILED DESCRIPTION
[0045] The present invention provides a method for coupling microspheres to proteins. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0046] In order to solve this problem, the present invention provides a method for coupling microspheres with proteins. By monitoring the particle size, dispersity and Zeta potential of the microspheres after activation and after coupling the microspheres with proteins, a method for coupling the microspheres with proteins is found, which can make the microspheres in a hydrophilic state with good dispersibility throughout the entire coupling process, thereby improving the activation efficiency of the microspheres and the coupling protein efficiency, and verifying that the method can increase the number of coupled antibodies.
[0047] The test materials used in the present invention are all common commercial products and can be purchased in the market. The present invention is further described below in conjunction with the embodiments.
[0048] Example 1: Labeling PCT antibody by washing microspheres with cleaning solution A
[0049] 1. Washing. Take 1000ug of microsphere suspension and put it into a centrifuge tube. The microspheres can be fluorescent microspheres. The acceptor microspheres used in this example are centrifuged at 18000rpm for 10-15min, and the supernatant is removed. Add 500ul of washing solution A (including 0.0001% SDBS + 0.01% sodium cholate) to suspend, disperse by ultrasound, centrifuge at 18000rpm for 10-15min, and remove the supernatant.
[0050] 2. Prepare the activator solution. Weigh the activators in advance. The activators are EDC and NHS. After the previous step is completed, add the activator diluent with a pH of 5 to 6 to the activators. The activator diluent is MES buffer to prepare a 5 mg / mL activator solution, which is ready for use.
[0051] 3. Activate the microspheres. Add 500ul of the activator diluent to 2, mix by ultrasonication, and then add 20ul-100ul of the activator solution. Incubate at 30°C and 800rmp for 30min. After activation, take out 10ul of the microspheres for later use, record as A-1, and proceed to the next step.
[0052] 4. Washing. After activation, centrifuge at 18000rpm for 10-15min and remove the supernatant. Add 500ul of washing solution A (including 0.0001% SDBS + 0.01% sodium cholate) to suspend, disperse by ultrasound, centrifuge at 18000rpm for 10-15min and remove the supernatant.
[0053] 5. Coupling. Add 500ul coupling buffer to suspend, the coupling buffer is pH7.0-8.0 Hepes buffer, ultrasonically mix, then add 5ug-150ug antibody or antigen, incubate at 30℃, 800rmp constant temperature for 2-4h. After the coupling is completed, take out 10ul microspheres for use, record as A-2, and then proceed to the next step.
[0054] 6. Collect and concentrate the supernatant. After the coupling is completed, take 200ul of the coupled solution, centrifuge at 18000rpm for 10-15min, collect the supernatant, concentrate the supernatant with a 30K ultrafiltration tube, record it as B-1, and store it at 2-8℃ for later use.
[0055] 7. Blocking. After the coupling is completed, mix the post-coupling solution and the precipitate from step 6, add 5-50ul of blocking solution for blocking. The blocking solution is BSA, and incubate at 30°C and 800 rpm for 30 minutes.
[0056] 8. Washing. After blocking, centrifuge at 18000rpm for 10-15min, remove the supernatant. Add 500ul of pure water to suspend, disperse by ultrasound, centrifuge at 18000rpm for 10-15min, remove the supernatant, add 500ul of microsphere preservation solution for storage, which can be 10mM Tris buffer, and store at 2-8℃ for future use.
[0057] In all embodiments of the present invention, in order to monitor the state of the microspheres during activation and coupling, a Malvern Panalytical particle size analyzer was used to detect the particle size, dispersity, zeta potential, and morphology of the microspheres, and the platenanoquant module of the Tecan Spark microplate reader was used to monitor the protein concentration.
[0058] Example 2: Labeling PCT antibody by washing microspheres with cleaning solution A
[0059] In this embodiment, the experimental method is the same as that in embodiment 1, except that:
[0060] In step 1, the microspheres are donor microspheres, and in steps 1 and 4, the cleaning solution A includes 0.01% SDBS + 0.0001% sodium cholate;
[0061] In step 2, the activator is glutaraldehyde, and the activator diluent is Hepes buffer;
[0062] In step 5, the coupling buffer is PBS buffer;
[0063] In step 7, the blocking solution is glycine;
[0064] In step 8, the microsphere storage solution is 200 mM Hepes buffer.
[0065] Example 3: Labeling PCT antibody by washing microspheres with cleaning solution A
[0066] In this embodiment, the experimental method is the same as that in embodiment 1, except that:
[0067] In step 1, the microspheres are receptor microspheres, and in step 1 and step 4, the cleaning solution A includes 0.005% SDBS + 0.005% sodium cholate;
[0068] In step 2, the activator is NaBH3CN, and the activator diluent is PBS buffer;
[0069] In step 5, the coupling buffer is a boric acid buffer;
[0070] In step 7, the blocking solution may also be a commonly used blocking agent such as ethanolamine, casein or carboxymethoxyamine;
[0071] In step 8, the microsphere storage solution is 100 mM PBS buffer.
[0072] The experiments show that the microspheres prepared in Examples 1 to 3 have similar dispersibility and antibody coupling efficiency.
[0073] Comparative Example 1: Using a common cleaning solution to clean the microspheres to label PCT antibodies
[0074] 1. Washing. Take 3 microsphere suspensions of 1000ug each and put them into centrifuge tubes. The microspheres can be fluorescent microspheres, donor microspheres, acceptor microspheres, etc. The acceptor microspheres used in this embodiment are centrifuged at 18000rpm for 10-15min, and the supernatant is removed. Add 500ul of pure water, 0.01M PBS buffer, and activation buffer to the 3 microspheres, suspend them, disperse them by ultrasound, centrifuge them at 18000rpm for 10-15min, and remove the supernatant.
[0075] 2. Prepare the activator solution. Weigh the activator in advance. The activator can be EDC, NHS, glutaraldehyde, NaBH3CN, etc. After the previous step is completed, add the activation buffer of pH 5~6 to the activator. The activation buffer can be MES, Hepes, PBS and other buffers to prepare a 5mg / ml activator solution, which is ready for use.
[0076] 3. Activate the microspheres. Add 500ul of activation buffer to 2, mix by ultrasonication, and then add 20ul-100ul of activator solution respectively. Incubate at 30℃, 800rmp for 30min. After activation, take out 10ul of microspheres for later use, record them as A-3, A-4, A-5 respectively, and proceed to the next step.
[0077] 4. Washing. After activation, centrifuge at 18000rpm for 10-15min and remove the supernatant. Add 500ul of pure water, 0.01M PBS buffer and coupling buffer to each of the three tubes for suspension, ultrasonic dispersion, centrifuge at 18000rpm for 10-15min and remove the supernatant.
[0078] 5. Coupling. Add 500ul coupling buffer to suspend. The coupling buffer can be Hepes, PBS, boric acid or other pH 7.0-8.0 buffer, mix by ultrasonic, then add 5ug-150ug antibody or antigen, incubate at 30℃, 800rmp constant temperature for 2-4h. After the coupling is completed, take out 10ul microspheres for use, record them as A-6, A-7, A-8, and then proceed to the next step.
[0079] 6. Collect and concentrate the supernatant. After the coupling is completed, take 200ul of the coupled solution, centrifuge at 18000rpm for 10-15min, collect 3 supernatants, concentrate the supernatants with a 30K ultrafiltration tube, record them as B-2, B-3, and B-4, and store them at 2-8℃ for later use.
[0080] 7. Blocking. After the coupling is completed, mix the coupling solution and the precipitate in step 6, add 5-50ul of blocking solution for blocking. The blocking solution can be a common blocking agent such as BSA, glycine, ethanolamine, casein, etc., and incubate at 30°C and 800rmp for 30 minutes.
[0081] 8. Washing. After the blocking is completed, centrifuge at 18000rpm for 10-15min, and remove the supernatant. Add 500ul of pure water to suspend, disperse by ultrasound, centrifuge at 18000rpm for 10-15min, remove the supernatant, and add 500ul of microsphere preservation solution for storage. The microsphere preservation solution can be 10Mm-200Mm Tris, Hepes, or PBS buffer, and store at 2-8℃ for future use.
[0082] Effect test protein control group
[0083] 1. Mix the same amount of coupling liquid and antibody as in Example 1 and Comparative Example 1, concentrate the supernatant using a 30K ultrafiltration tube, record it as B-5, and store it at 2-8°C for later use.
[0084] Experiment 1
[0085] 1. The activated and coupled microspheres A-1 to A-8 obtained from the four labeling methods in Example 1 and Comparative Example 1 were tested by a particle size analyzer.
[0086] 2. The experimental results are shown in Table 1 below.
[0087] Table 1
[0088]
[0089] 3. Results Analysis
[0090] From the experimental results, it can be seen that the particle size of A-1 and A-2 microspheres obtained after activation and coupling in Example 1 is normal, the dispersibility meets the requirements (PDI≤0.2), and the Zeta potential value is large. The larger the potential value, the better the colloid stability of the microspheres; A-3~A-8 all have large particle sizes, poor dispersibility, and small potential values. In summary, it is shown that the labeling method in Example 1 can make the microspheres have good dispersibility after activation and coupling, and the microspheres are in a relatively stable state.
[0091] Experiment 2
[0092] 1. The antibody concentrations of the supernatant concentrates B-1, B-2, B-3, B-4 and B-5 obtained from Example 1, Comparative Example 1 and Effect Example were respectively detected using the plate nanoquant module of the Tecan Spark microplate reader.
[0093] The experimental results are shown in Table 2 below.
[0094] Table 2
[0095]
[0096] 2. Results Analysis
[0097] From the experimental results, it can be seen that the antibody content in the supernatant after coupling in Example 1 is lower than that in the three groups of experiments in Comparative Example 1, indicating that the amount of microsphere-coupled antibodies in Example 1 is more than that in Comparative Example 1, which also shows that the improved cleaning method of the present invention can improve the protein coupling efficiency.
[0098] Experiment 3
[0099] 1. The four microspheres labeled with PCT antibodies in Example 1 and Comparative Example 1, which were labeled in four ways, were diluted 500 times with a microsphere diluent containing 100 mM PBS, 0.9% Nacl, 1% BSA, 0.05% proclin300, pH 7.4 buffer, and were recorded as Rb-1, Rb-2, Rb-3, and Rb-4, respectively.
[0100] 2. The Ra component (another monoclonal PCT antibody coated with biotin) was diluted 500 times with 100mM PBS, 0.9% Nacl, 1% BSA, 0.05% proclin300, pH 7.4 buffer. The Rc component (donor microspheres coated with streptavidin) was diluted 500 times with 100mM PBS, 0.9% Nacl, 1% BSA, 0.05% proclin300, pH 7.4 buffer.
[0101] 3. Divide Ra and Rc into 4 parts respectively, and match them with Rb-1, Rb-2, Rb-3, and Rb-4 to form 4 PCT kits.
[0102] 4. The above four PCT kits were tested for PCT enterprise repeatability reference materials 0.5ng / mL (level 1) and 20ng / mL (level 2), respectively, and the measurements were repeated three times.
[0103] 5. The experimental results are shown in Table 3 below.
[0104] Table 3
[0105]
[0106] 6. Results Analysis
[0107] It can be seen from the test results that the background of Rb-1, Rb-2, Rb-3, and Rb-4 groups is not much different, but the signal of the reference product of the Rb-1 group is significantly higher than that of the Rb-2, Rb-3, and Rb-4 groups. Combined with the results in Comparative Example 1, it can be concluded that in Example 1 and Comparative Example 1, the antibody coupling efficiency of Example 1 is higher, thereby improving the sensitivity of the reagent. Although in the actual application of in vitro diagnostic reagents, the more antibodies are coupled, the better the performance, but the microsphere protein coupling method provided by the present invention can reduce the amount of antibody used by improving the coupling efficiency, thereby achieving the purpose of saving costs.
[0108] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for coupling microspheres to proteins, It is characterized in that The steps include: Step 1, mixing the microspheres with a cleaning solution and then performing ultrasonic cleaning; Step 2, activating the microspheres cleaned in step 1; Step 3, taking the activated microspheres and mixing them with the cleaning solution, and then ultrasonically cleaning them again; Step 4, mixing the microspheres washed in step 3 with the protein for coupling reaction; Step 5, taking the microspheres after coupling in step 4, blocking them, and obtaining a conjugate of microspheres and protein; The cleaning solution comprises sodium dodecylbenzene sulfonate and sodium cholate.
2. The method according to claim 1, It is characterized in that Each 100 mL of the cleaning solution contains 0.0001-0.01 g of sodium dodecylbenzene sulfonate and 0.0001-0.01 g of sodium cholate.
3. The method according to claim 1 or 2, It is characterized in that In step 1, the microspheres include at least one of fluorescent microspheres, donor microspheres and acceptor microspheres.
4. The method according to any one of claims 1 to 3, It is characterized in that In step 1 and step 3, after the ultrasonic cleaning, the method further comprises centrifuging the microspheres and discarding the supernatant, wherein the centrifugal speed is 10000-20000 rpm and the centrifugal time is 10-15 min.
5. The method according to any one of claims 1 to 4, It is characterized in that In the step 2, the activation includes mixing the microspheres and the diluent by ultrasonication, adding an activator, mixing, shaking and incubating.
6. The method according to claim 5, It is characterized in that The activating agents include EDC, NHS, glutaraldehyde and NaBH 3 CN, wherein the diluent comprises at least one of MES buffer, Hepes buffer and PBS buffer; The activation reaction temperature is 25-40° C., and the shaking incubation is performed at 500-1000 rpm for 15-30 min.
7. The method according to any one of claims 1 to 6, It is characterized in that In step 4, the coupling reaction includes taking a coupling buffer to suspend the washed microspheres, mixing with the protein, and incubating by shaking.
8. The method according to claim 7, It is characterized in that The coupling buffer comprises at least one of Hepes buffer, PBS buffer and boric acid buffer, and the protein comprises an antibody or an antigen; In the incubation solution, the concentration of the microspheres is 30-70% (w / v), the concentration of the protein is 1%-30% (w / v), the incubation temperature is 25-40° C., and the shaking incubation is performed at 500-1000 rpm for 2-4 hours.
9. The method according to any one of claims 1 to 8, It is characterized in that In step 5, the blocking comprises taking the microspheres and shaking and incubating them with a blocking solution, wherein the blocking solution comprises at least one of BSA, glycine, ethanolamine, casein and carboxymethoxyamine, the blocking reaction temperature is 25-40°C, and the blocking is performed by shaking and incubating at 500-1000 rpm for 15-30 minutes.
10. The method according to any one of claims 1 to 9, It is characterized in that The sealed solution is centrifuged, the supernatant is discarded, and then ultrasonically cleaned and centrifuged again with water. The obtained precipitate is mixed with a buffer and stored, wherein the buffer includes at least one of Tris buffer, Hepes buffer and PBS buffer, and the storage temperature is 2-8°C.
Citation Information
Patent Citations
Microsphere for amplifying signal of ELISA (Enzyme-Linked Immunosorbent Assay) kit and preparation method of microsphere
CN114324857A
Kit and detection method for related markers of central nervous degenerative disease
CN117434269A
